Tango Therapeutics, Inc. short interest in 2022
In 2022, Tango Therapeutics, Inc.'s disclosed short interest ran from 2.35% of shares outstanding on 14 Jan 2022 to 1.66% on 30 Dec 2022, a change of -0.69 percentage points. The year's high was 3.54% on 31 Mar 2022 and its low 1.20% on 30 Sep 2022, averaging 2.03% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.98 days on 15 Feb 2022. Full history: Tango Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 2.35% (14 Jan 2022)
- End of year
- 1.66% (30 Dec 2022)
- Change
- -0.69 pp
- High
- 3.54% (31 Mar 2022)
- Low
- 1.20% (30 Sep 2022)
- Average
- 2.03%
- Highest days to cover
- 20.98 (15 Feb 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 2.35% | 14.13 | |
| 31 Jan 2022 | 2.40% | 16.97 | |
| 15 Feb 2022 | 2.40% | 20.98 | |
| 28 Feb 2022 | 2.40% | 13.40 | |
| 15 Mar 2022 | 2.52% | 10.45 | |
| 31 Mar 2022 | 3.54% | 6.03 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 3.43% | 15.28 | |
| 29 Apr 2022 | 3.53% | 15.70 | |
| 30 Jun 2022 | 2.09% | 1.62 | 10-Q filed, results (8-K) |
| 15 Jul 2022 | 1.91% | 8.51 | |
| 29 Jul 2022 | 1.85% | 5.82 | |
| 15 Aug 2022 | 1.55% | 4.75 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 1.48% | 11.00 | |
| 15 Sep 2022 | 1.59% | 6.76 | |
| 30 Sep 2022 | 1.20% | 4.12 | |
| 14 Oct 2022 | 1.25% | 6.84 | |
| 31 Oct 2022 | 1.42% | 4.76 | |
| 15 Nov 2022 | 1.46% | 5.22 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 1.45% | 6.40 | |
| 15 Dec 2022 | 1.23% | 5.70 | |
| 30 Dec 2022 | 1.66% | 5.69 |
See also: Tango Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.